In mouse models, anti-CTLA4 antibody treatment initially resulted in the rejection of tumors, including preestablished tumors; furthermore, the rejection resulted in immunity to a secondary exposure to tumor cells (33). The gene discussed is CTLA4; the disease is neoplasm.